Allergan has been working on a sustained-release glaucoma implant.

What is it?
It’s called Bimatoprost SR and it’s a biodegradable implant that dispenses bimatoprost (aka Lumigan) for at least 4 months. It’s injected into the anterior chamber and is visible in the inferior iridocorneal angle where it slowly dispenses medication and degrades.

How much IOP reduction?
In their Phase 3 trial, it reduced IOP by 30% over 12 weeks which is similar to topical prostaglandins.

When will this be a thing?
Not until next year. Allergan plans to submit a new drug application to the FDA in 2019. (via)